Cardiometabolic Index as a predictor of mortality in metabolic Dysfunction-Associated Steatotic Liver Disease

Abstract Background Cardiometabolic Index (CMI) is positively correlated with liver fibrosis in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), but its association with mortality risk in MASLD patients remains unclear. Methods This study utilized data from NHANES III...

Full description

Saved in:
Bibliographic Details
Main Authors: Yang Yang, Cheng Zeng, Zhiqiang Jin, Yi Huang, Huabao Liu
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Gastroenterology
Subjects:
Online Access:https://doi.org/10.1186/s12876-025-04127-z
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849333416298807296
author Yang Yang
Cheng Zeng
Zhiqiang Jin
Yi Huang
Huabao Liu
author_facet Yang Yang
Cheng Zeng
Zhiqiang Jin
Yi Huang
Huabao Liu
author_sort Yang Yang
collection DOAJ
description Abstract Background Cardiometabolic Index (CMI) is positively correlated with liver fibrosis in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), but its association with mortality risk in MASLD patients remains unclear. Methods This study utilized data from NHANES III and linked it with the mortality database up to December 31, 2019. Cox regression analysis was used to examine the relationship between CMI and mortality rates. Linear regression analysis was conducted to explore the correlation between CMI and the TyG index, and mediation analysis was performed to investigate the potential mechanisms underlying the association between CMI and mortality. Results The study included 2,260 MASLD patients with a median age of 51 years and a median CMI of 2.5. In the fully adjusted Cox regression model, CMI was positively associated with all-cause mortality (per 1-SD increase, HR = 1.04, 95% CI = 1.00-1.08) and other-cause mortality rates (per 1-SD increase, HR = 1.25, 95% CI = 1.12–1.40), but not with cardiovascular or cancer-related mortality. Mediation analysis indicated that the TyG index mediated 16.6% of the association between CMI and all-cause mortality. Conclusion CMI in MASLD patients is associated with an increased risk of all-cause and other-cause mortality.
format Article
id doaj-art-aba246289d114c03b482f94fe1b9b46d
institution Kabale University
issn 1471-230X
language English
publishDate 2025-07-01
publisher BMC
record_format Article
series BMC Gastroenterology
spelling doaj-art-aba246289d114c03b482f94fe1b9b46d2025-08-20T03:45:52ZengBMCBMC Gastroenterology1471-230X2025-07-0125111210.1186/s12876-025-04127-zCardiometabolic Index as a predictor of mortality in metabolic Dysfunction-Associated Steatotic Liver DiseaseYang Yang0Cheng Zeng1Zhiqiang Jin2Yi Huang3Huabao Liu4Chongqing Traditional Chinese Medicine HospitalDepartment of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, the Second Affiliated Hospital, Chongqing Medical UniversityDepartment of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, the Second Affiliated Hospital, Chongqing Medical UniversityChongqing Traditional Chinese Medicine HospitalChongqing Traditional Chinese Medicine HospitalAbstract Background Cardiometabolic Index (CMI) is positively correlated with liver fibrosis in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), but its association with mortality risk in MASLD patients remains unclear. Methods This study utilized data from NHANES III and linked it with the mortality database up to December 31, 2019. Cox regression analysis was used to examine the relationship between CMI and mortality rates. Linear regression analysis was conducted to explore the correlation between CMI and the TyG index, and mediation analysis was performed to investigate the potential mechanisms underlying the association between CMI and mortality. Results The study included 2,260 MASLD patients with a median age of 51 years and a median CMI of 2.5. In the fully adjusted Cox regression model, CMI was positively associated with all-cause mortality (per 1-SD increase, HR = 1.04, 95% CI = 1.00-1.08) and other-cause mortality rates (per 1-SD increase, HR = 1.25, 95% CI = 1.12–1.40), but not with cardiovascular or cancer-related mortality. Mediation analysis indicated that the TyG index mediated 16.6% of the association between CMI and all-cause mortality. Conclusion CMI in MASLD patients is associated with an increased risk of all-cause and other-cause mortality.https://doi.org/10.1186/s12876-025-04127-zCardiometabolic indexMASLDMortalityTriglyceride-glucose indexNHANES
spellingShingle Yang Yang
Cheng Zeng
Zhiqiang Jin
Yi Huang
Huabao Liu
Cardiometabolic Index as a predictor of mortality in metabolic Dysfunction-Associated Steatotic Liver Disease
BMC Gastroenterology
Cardiometabolic index
MASLD
Mortality
Triglyceride-glucose index
NHANES
title Cardiometabolic Index as a predictor of mortality in metabolic Dysfunction-Associated Steatotic Liver Disease
title_full Cardiometabolic Index as a predictor of mortality in metabolic Dysfunction-Associated Steatotic Liver Disease
title_fullStr Cardiometabolic Index as a predictor of mortality in metabolic Dysfunction-Associated Steatotic Liver Disease
title_full_unstemmed Cardiometabolic Index as a predictor of mortality in metabolic Dysfunction-Associated Steatotic Liver Disease
title_short Cardiometabolic Index as a predictor of mortality in metabolic Dysfunction-Associated Steatotic Liver Disease
title_sort cardiometabolic index as a predictor of mortality in metabolic dysfunction associated steatotic liver disease
topic Cardiometabolic index
MASLD
Mortality
Triglyceride-glucose index
NHANES
url https://doi.org/10.1186/s12876-025-04127-z
work_keys_str_mv AT yangyang cardiometabolicindexasapredictorofmortalityinmetabolicdysfunctionassociatedsteatoticliverdisease
AT chengzeng cardiometabolicindexasapredictorofmortalityinmetabolicdysfunctionassociatedsteatoticliverdisease
AT zhiqiangjin cardiometabolicindexasapredictorofmortalityinmetabolicdysfunctionassociatedsteatoticliverdisease
AT yihuang cardiometabolicindexasapredictorofmortalityinmetabolicdysfunctionassociatedsteatoticliverdisease
AT huabaoliu cardiometabolicindexasapredictorofmortalityinmetabolicdysfunctionassociatedsteatoticliverdisease